OUR TEAM

Board

Tomas Kramar

Chairman

Tomas has a Master of Science in Chemical Engineering from Lund University. He has over 40 years of experience from the life science industry and has previously worked as CEO of Siemens Healthineers, as well as CEO of Siemens Healthcare Diagnostics. Tomas has also worked at Abbott Laboratories, Becton Dickinson and Hoffmann La Roche. Tomas is chairman of Kramar Group AB and the Percy Falk Cancer Foundation. He is also a board member of Nanologica AB, Gentian A / S, Corsmed AB, Lundonia Biotech AB and CytaCoat AB.

Masoud Khayyami

Member

Masoud has a PhD in technical chemistry and has solid experience from research in medical technology and biotechnology. He has previously been both CEO and board member of SpectraCure AB. Masoud has entrepreneurial experience in companies such as Lumito AB, Gasporox AB and Prolight Diagnostics AB.

Ulf Bladin

Member

Bachelor of Medicine from Karolinska Institutet, Master of Business Administration and Master’s from the Stockholm School of Economics. Currently CEO of Prolight Diagnostics (publ.). Has previously been General Manager, Vice President of the EMEA region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, Vice President with Global Responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia AB. Ulf Bladin has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dhome.
Ulf is currently CEO and board member of Prolight Diagnostics AB (publ.), Board member of SpectraCure AB (publ.), SPCIN AB and UB Management Invest AB.

Thomas Jensen

Member

Thomas Jensen is a pure researcher as a worker in oncology. He is the founder of a US Nasdaq-listed medtech oncology company. Thomas has also been very active with capital raising, investor relations, commercialization and IPOs in Denmark, Sweden and the USA. Thomas also currently serves as board member of Allarity Therapeutics, a clinical-stage precision medicine company publicly traded on the NASDAQ.

Senior partners

Katarina Svanberg

Katarina Svanberg has an M.D., PhD and has for a long time been chief physician and adjunct professor of oncology at Lund University. She has been a part-time professor at South China Normal University in Guangzhou, China since 2011. Katarina has introduced photodynamic tumor therapy in clinical use at Lund University Hospital. She has received the US Medicines Agency’s award in laser medicine, and the optics and laser organization SPIE’s highest reward; its gold medal.

Sune Svanberg

Sune Svanberg is a senior professor of physics at Lund University. He has been director of the Department of Atomic Physics for 30 years and of the Lund Laser Center for 15 years, as well as a member of the Nobel Committee in Physics for 10 years. Sune has been awarded around 20 international and national prizes and holds five honorary doctorates and four honorary professorships. Since 2011, Sune also holds a part-time professorship at South China Normal University, Guangzhou, China.

Ingemar Kihlström

Bachelor of Arts in Chemistry and Biology, Doctor of Physiology from Uppsala university, and Associate Professor at Uppsala University. Consultant in biotechnology and finance. Has previously worked with research and business development at both Astra AB and Pharmacia AB. Thereafter, as a pharmaceutical analyst in the financial industry, e.g. at Swedbank, Aros Securities and ABG Sundal Collier. Today Chairman of the Board of, among others, Miris Holding, SpectraCure and EQL Pharma.

Stefan Andersson-Engels

Professor of Physics at Lund University until 2016. Since 2016 Director of Biophotonics at Tyndall National Institute, Ireland. Post-doc at McMasters University in Hamilton, Ontario, Canada. Received the Erna Ebeling Prize, Swedish Society for Medical Technology and Physics, 2003. Co-author of more than 200 articles in peer-reviewed journals.

Ulf Bladin

Bachelor of Medicine from Karolinska Institutet, Master of Business Administration and Master from the Stockholm School of Economics. Currently CEO at Prolight Diagnostics. Has previously been i.e. General Manager, Vice President of the EMEA Region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division.

Johannes Swartling

Extensive experience in commercializing research results in the role of CTO at SpectraCure and former CTO at Gasporox and GPX Medical. Expertise in product development for medical technology systems.